molsidomine
Molsidomine (trade names Corvasal, Corvaton and many others) is an orally active, short acting vasodilating drug used to treat angina pectoris. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.
Key facts
- Drug.IUPAC_name
- 1-Ethoxy-N-(3-morpholino-5-oxadiazol-3-iumyl)methanimidate
- Drug.image
- Molsidomine.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Corvasal, Corvaton, Molsidain, Molsidolat, others
- Drug.routes_of_administration
- By mouth (tablets), intravenous infusion
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 44–59%
- Drug.protein_bound
- 3–11%
- Drug.metabolism
- Hydrolysis
- Drug.metabolites
- Linsidomine
- Drug.elimination_half life
- 1–2 hrs (linsidomine)
- Drug.excretion
- >90% renal
Article
11 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- References
Molsidomine (trade names Corvasal, Corvaton and many others) is an orally active, short acting vasodilating drug used to treat angina pectoris. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.
==Medical uses== Molsidomine is used for the prevention and long-term treatment of stable and unstable angina pectoris, with or without left heart failure. It is also used to treat angina in the context of an acute myocardial infarction.